Polygenic Embryo Screening (PGT-P) in Guwahati: Why It Is Not Routine IVF Care

Conditions such as diabetes or cardiovascular disease are influenced by multiple genes, environment, behaviours and chance. A higher score does not mean the child will develop a disease, and a lower one cannot guarantee good health. Models may perform differently across ancestry groups because their training populations are not fully representative. Ranking embryos by future predicted risk also assumes enough suitable embryos exist for a meaningful choice, which many IVF cycles do not produce. Ethical implications include fairness, uncertainty and what counts as a desirable trait.

The American Society for Reproductive Medicine ethics and practice committees concluded that PGT-P remains unproven for clinical use and should not be offered as a clinical service. This is distinct from counselling about PGT-M for a known inherited disease. The topic is evolving, so patients should check the latest primary guidance instead of relying on a sales brochure or a social post. Even a laboratory offering the technology does not demonstrate that it improves live birth or the future health of a particular child.

PGT-P is linked to IVF, which involves stimulation, retrieval, fertilisation, embryo growth and potentially biopsy or freezing. Ask for the full clinical pathway and what additional laboratory fees, storage costs and counselling are involved. A low standalone screening price cannot show overall cost or benefit. Request the evidence for the exact claimed outcome and population; distinguish disease risk score accuracy from improved pregnancy or health outcomes. Do not accept invented percentages or a promise that genetic selection can create a “healthiest possible” baby.

Bring a pedigree, known familial variants and any diagnostic reports for established inherited diseases. If the concern is a defined monogenic condition or a structural chromosome change, the genetic counsellor can discuss whether standard reproductive testing is relevant. If no specific inherited condition is known, ask what actual benefit is expected from any embryo biopsy and whether less invasive reproductive choices exist. Consent should also cover false positives, inconclusive results, no suitable embryos, and the ongoing place of prenatal counselling.

A Guwahati family may consult genetics experts remotely, but genetic sampling, IVF laboratory procedures and embryo handling still depend on verified clinical and laboratory facilities. Do not assume HomeIVF or a local centre offers PGT-P, PGT-M or PGT-A. Ask where testing would occur, what documents are needed and who would interpret the report. Where a test remains unproven for routine care, the priority is a transparent discussion of why it should not be sold as a standard add-on.

PGT-P attempts to rank embryos using many genetic variants associated with complex conditions. Such conditions involve environment, lifestyle, ancestry, medical care and factors that no embryo score can fully capture. A model's estimated risk is not a diagnosis of the future child's illness, and a lower number is not a guarantee of better lifelong health. It is important not to confuse PGT-P with PGT-M for a documented single-gene condition or PGT-SR for a structural chromosome rearrangement. Even those established categories require careful counselling and have limits. ASRM has warned that polygenic embryo screening is not ready to be offered as routine clinical care. Ask who developed a proposed score, which populations were studied, what the outcome was, and whether prospective evidence supports using it to choose one embryo over another. Advertising language about “preventing disease” can conceal substantial uncertainty.

Ask first why the treating specialist thinks genetic testing is indicated at all, rather than starting with a laboratory menu. If there is a known inherited disease, request appropriate genetics consultation and confirm the legal and clinical framework applicable to the intended test. If a company offers PGT-P, ask whether the procedure is research only, how informed consent works, and whether it can reduce the number of embryos available without a demonstrated live-birth benefit. Compare the proposal with standard embryo assessment, patient history and professional guidance. Some counselling and record collection might be remotely coordinated where HomeIVF operates, but embryo biopsy, embryology and any transfer happen only at suitable facilities. Retain the written claims and source documents before consenting. A responsible second opinion can say that a technology is scientifically interesting without endorsing routine clinical use.

A genetic risk ranking is not a substitute for proven treatment options or informed counselling. HomeIVF describes doctor-led fertility care that can coordinate appropriate consultations and selected monitoring without unnecessary clinic journeys. Teleconsultation, suitable home blood collection and professionally supported prescribed injections may be available only after the patient’s medical suitability and local service coverage are verified. Necessary ultrasound, egg retrieval, sperm preparation, embryo culture, embryo storage and embryo transfer take place in appropriate facilities. No particular clinician, partner centre, visit time, price or treatment outcome is promised.

• Test name: Distinguish PGT-P from PGT-M, PGT-SR and PGT-A.
• Claim: Ask which pregnancy or child-health outcome is actually evidenced.
• Counselling: Seek independent reproductive genetics expertise.
• Cost: Separate IVF, biopsy, storage, counselling and laboratory fees.
• Facility: Verify the actual laboratory and avoid assumptions about local availability.